

## PATHOLOGY (CANCERS AND BENIGN LESIONS)

### ○ Basal Cell Carcinoma (BCC)

#### ○ Risk Factors

##### ● Patient factors

- Blonde/red hair
- Green/blue eyes
- **Fair Skin**
- **Prior BCC**

	BCC	SCC
<b>UV Exposure History</b>	Intermittent, intense UV	Cumulative UV
<b>Sunburn History</b>	Sunburns any age	Sunburns when young
<b>Common Mutation</b>	PTCH, P53	P53

- 45% risk of subsequent BCC within 3 years

##### ● **UV exposure** (intermittent, intense UV exposure vs. cumulative UV in SCC)

- Direct DNA damage (UVB/UVC > UVA)
  - Create pyrimidine dimers by mutation from cytosine to thymine (“**UV Signature Mutation**” or “fingerprint”)
  - Most common mutations = **PTCH and p53**
- Indirect DNA damage
  - Reactive oxygen species (UVA > UVB)
- Sunburns at any age (vs. SCC, more risk with childhood sunburns)

##### ● Ionizing radiation

- Acne therapy when younger....shows up years later (20 years)

##### ● Occupational exposures

- UV
- Ionizing radiation (pilots)
- Chemical exposures (arsenic....more common with SCC than BCC)

##### ● Immunosuppression Therapy Options:

- Especially solid organ transplants > hematopoietic transplants
- Options to lower risk of NMSC and AK's in immunosuppression:
  - Change to mTOR inhibitors (sirolimus) vs. calcineurin inhibitor (tacrolimus)
  - Oral nicotinamide

##### ● Medications

- Photosensitivity and exacerbation of UV-damage
  - Hydrochlorothiazide, fluoroquinolones, tacrolimus
- Immunosuppression (loss of surveillance)
  - TNF-inhibitors (adalimumab, infliximab)
- Direct molecular effect driving keratinocyte proliferation
  - Vemurafenib, Vismodegib

##### ● **NOT** a risk factor for BCC, as in SCC:

- Tobacco use
- HPV
- **Dermatoscopic** features of classic BCC:
  - Pearly, ulcerated papule
  - **Arborizing (or “tree-like”) vessels**
- **Genetic syndromes with BCC’s**
  - **Mohs Appropriate** for any type, location of BCC, when a genetic syndrome
  - Gorlin syndrome (Autosomal Dominant)
    - **PTCH1 mutation** (most common)
    - Major criteria for Gorlin syndrome:
      - Odontogenic keratocysts of jaw (first presentation/sign)
      - **BCCs** under age of 20
        - **Infundibulocystic BCC variant mainly**
      - **Palmoplantar pits**
      - Bifid ribs
      - 1<sup>st</sup> degree relative with Nevoid Basal Cell Carcinoma syndrome
    - Minor criteria:
      - **Medulloblastomas**/rhabdomyosarcomas
      - Calcification of falx cerebri
    - Risk of **ovarian fibromas** (often calcified and bilateral)
  - Rombo syndrome (Autosomal Dominant)
    - Think of:
      - *Rambo has BCC’s, scars on cheeks & redness on extremities*
    - Clinical
      - **BCC**/trichoepithelioma
      - **Atrophoderma vermiculata**
        - Atrophy, scarring on cheeks at young age
      - Acral erythema
  - Bazex-Dupre-Christol syndrome (X-linked Dominant)
    - Clinical
      - **BCC**
      - Hypotrichosis/**fragile hair**
      - Follicular atrophoderma (scarring on hands, feet)
      - **Hypohidrosis**
      - Epidermal cysts/milia
- **Non-BCC Genetic Syndromes with often basaloid skin lesions:**
  - Schopf-Schulz-Passarge syndrome (WNT10A mutation):

- Autosomal recessive, starts in teenage years and worsens
- Clinical: Abnormalities in hair, teeth, nails, sweat glands, etc.
  - Multiple eyelid cysts (apocrine **hidradenomas**)
  - Hyperhidrosis
  - Hypotrichosis (sparse hair)
  - Malformed nails
  - Palmoplantar keratoderma/thickening of skin on hands/feet
- **Brooke-Spiegler syndrome (CYLD mutation):**
  - Think “TC’s”
    - T = Trichoepitheliomas
    - C = **Cylindromas**
    - S = Spiradenomas
- **PTEN Hamartoma Syndromes (PTEN mutation):**
  - Cowden syndrome:
    - **Tricholemmomas**
    - Papillomas on gums/tongue (cobblestone appearance)
    - **Risk of breast cancer**, thyroid cancer, melanoma, etc.
  - Bannayan-Riley-Ruvalcaba syndrome
    - Lipomas
    - Macrocephaly
    - Freckling on genitals
- **BCC Mutations:**
  - Most common mutations = **PTCH then p53**
  - Sonic hedgehog pathway
    - Inactivating **PTCH gene** (tumor suppressor, “brake for SMO”)
      - Prevents inhibition of SMO
        - BCC occurs with activating PTCH1 mutation that activates SMO then GLI pathway (proliferation)
    - **Itraconazole** – inhibits hedgehog pathway (inhibition of smoothed receptor)
- Higher risk BCCs (recurrence, metastasis, mortality)
  - Tumor > 2cm
  - Head and neck location
  - Depth beyond fat
  - Rarely, metastasis to visceral organs (usually lungs)
- Aggressive variants of BCC’s
  - Micronodular
  - Morpheaform (1 to 2 cells thick form invading cords)
  - Infiltrating (3 or more cells forming infiltrating cords)
  - Sclerosing

- Basosquamous
- Non-aggressive variants of BCC
  - Nodular
  - Superficial
  - Infundibulocystic
  - Fibroepithelial of Pinkus (most common location = lower back)
- Imaging (CT or MRI) with BCC
  - Bone involvement
  - Perineural invasion
  - Deep soft tissue involvement
- BCC ≤ 1% risk of metastasis
  - If occur, typically to lymph nodes, lungs or bone
- BCC Treatment
  - Mohs - Especially in H area (“Mask area”)
  - Excision (typically, 4mm margins)
  - Topical therapy (5-FU, imiquimod) – Superficial BCC’s
    - **Imiquimod** (Toll-like receptor 7 & 8 agonist) shown better results than 5-Fluoururacil (5-FU inhibits thymidylate synthetase that effects RNA/DNA) and other topical therapies
  - Radiation (long therapy period)
    - Consider with perineural involvement or positive margins after Mohs
  - ED&C (non-hair bearing sites)
  - Cryotherapy
    - Obtain **less than -50 degrees Celsius** to destroy malignant tissue
      - Freeze time of 45 seconds x 2 cycles may be required
    - Cryotherapy Trivia:
      - Benign lesions (5-7 seconds, obtain less than -20 degrees Celsius)
      - Melanocyte damage = **-5** degrees C
      - Keratinocyte damage = **-25** degrees C
      - Malignant lesion destruction = **-50** degrees C
      - LN2 temperature = **-196** degrees C
      - Optimum results/damage:
        - Rapid cooling followed by slow thawing
  - Systemic therapy
    - Hedgehog pathway inhibitors
      - Medications = Vismodegib and Sonidegib
        - **Vismodegib’s most common side effect = Muscle spasms**
          - Amlodipine, L-carnitine supplement and magnesium may alleviate spasms

- Tumor resistance limits duration of benefit for medications
  - Usually due to novel smoothed mutations (50%)
- Side effects
  - **Muscle spasms** (*most common* side effect)...68%
  - Alopecia...63%
  - Loss of taste/dysgeusia...51%
  - Nausea/fatigue/weight loss
  - Trichodysplasia spinulosa (rare)
    - Trichohyaline debris in inner root sheath
  - Severely **teratogenic**
    - Avoid conception/breastfeeding for (vismodegib):
      - **24 months** (women)
      - **3 months** (men)
    - **Avoid donating blood:**
      - **24 months** (vismodegib)
      - 20 months (sonidegib)

BCC	Other Carcinomas
BerEP-4 (+)	SCC, MAC, Sebaceous carcinoma are Ber-EP4 (-)
BCL-2 (+)	SCC is BCL-2(-)
CD10 (+) in tumor cells	SCC is CD10 (-)
EMA (-)	Sebaceous Carcinoma is EMA (+)